EUnetHTA Joint Action 3 (2016-20)

Home  /  Outputs   /  EUnetHTA Joint Action 3 (2016-20)

This is the assessment of the relative effectiveness of  ‘Sotagliflozin indicated as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus with a Body Mass Index (BMI) ≥ 27 kg/m2, who have failed

EUnetHTA recently started a new Collaborative Assessment on a Medical Device for rectum spacers for prostate cancer radiotherapy. To find out about participation, please read more here. Input submissions will be received through EOB, Friday 5th July.

EUnetHTA recently started a new Joint Assessment on a medicinal product for neovascular (wet) age-related macular degeneration (AMD). To find out about participation, please read more here. Input submissions will be received through 13:00, July 15th.

The Final OTCA18 Project Plan on 'Regional hyperthermia for high-risk soft tissue sarcoma treatment' is now available for access, together with comments from external experts, Haukeland Hospital, and manufacturers, and the relevant answers for each from the assessment team. Please access

  The Haute Autorité de Santé (HAS), National Institute for Health and Care Excellence (NICE) & the Croatian Institute for Public Health (HZJZ) are pleased to share the following WP5 strand B draft outputs for an 8 week public consultation:   REQueST (Registry Evaluation

  To accompany the upcoming EUnetHTA 2019 Assembly & Forum 0n 10-11th April in Amsterdam, a Welcome Guide has been developed to give participants and attendees a thorough overview of the event proceedings, practical information, and EUnetHTA's working activities. The guide is

EUnetHTA has developed documentation to address Conflict of Interest (COI) concerns and assist in the decision-making process relating to the assessment of individuals potentially involved in EUnetHTA JA3 activities. The Procedure Guidance for handling Declaration of Interest and Confidentiality Undertaking